CICLUM FARMA UNIPESSOAL, LDA secures contract for 1753/2025- Acquisition Of B771- Bevacizumab [25 Mg/Ml; 400 Mg/ 16 Ml; Conc For Sol For Infusion; Frs] Patients Undergoing Treatment And U41- Ustekinumab [45 Mg/ 0.5 Ml; Sun Inj; Syringe] - Patients Undergoing Treatment

Portugal, Nov. 20 -- Portugal based CICLUM FARMA UNIPESSOAL, LDA has secured contract from Unidade Local De Saude De Sao Jose, E. P. E. for 1753/2025- Acquisition Of B771- Bevacizumab [25 Mg/Ml; 400 Mg/ 16 Ml; Conc For Sol For Infusion; Frs] Patients Undergoing Treatment And U41- Ustekinumab [45 Mg/ 0.5 Ml; Sun Inj; Syringe] - Patients Undergoing Treatment. The value of the contract is worth 7302200 EUR.

Published by HT Digital Content Services with permission from Pivotal Sources....